45 results about "Glycoconjugate" patented technology

The present invention relates to sulforaphane glycoconjugate compounds, as well as to the synthesis and therapeutic uses thereof for treating inflammatory diseases.

The present invention relates to a large scale GMP synthesis method of a modified glucan conjugate, and more particularly, to a glucan-guanidine-bisphosphonate conjugate wherein the bisphosphonate is an alendronate group. The large-scale GMP synthesis method related to the invention can be used for producing the glucan-guanidine-bisphosphonate conjugate with high purity and medicinal grade. The invention also relates to an application of the glucan-guanidine-bisphosphonate conjugate in a medicine for treating tumors.

The present invention relates to a method for producing α-sialyl-β-D-galactoside saccharides, particularly α-sialyl-(2→3)-β-D-galactoside saccharides and α-sialyl-(2→6)-β-D-galactoside saccharides, from a β-D-galactoside saccharide, a sialic acid donor, and an enzyme with β-galactoside α-sialyltransferase activity. The enzymes with β-galactoside α-sialyltransferase activity used herein do not exhibit catalytic activity towards the hydrolysis of cytidine 5'-monophospho-N-acetyl-neuraminic acid to cytidine and N-acetyl-neuraminic acid. The method can be performed in vitro and in vivo using a genetically engineered cell comprising a nucleic acid encoding said enzyme. Further, said process may be adapted to produce the sialic acid donor CMP-Neu5Ac from low-cost substrates N-acetyl-D-glucosamine (GlcNAc), pyruvate, a cytidine phosphate (CMP, CDP or CTP) and polyphosphate in a single reaction mixture with a set of optionally immobilized or optionally co-immobilized enzymes comprising N-acylglucoamine 2-epimerase (AGE), an N-acetylneuraminate lyase (NAL), an N-acylneuraminate cytidylyltransferase (CSS), optional a uridine kinase (UDK), a uridine monophosphate kinase and a polyphosphate kinase 3 (PPK3).

A method of making a chitosan conjugate, the method comprising: contacting chitosan, a dicarboxylic acid, and 4-(4, 6-dimethoxy-1, 3, 5-triazin-2-yl)-4-methyl-morpholinium chloride (DMTMM) in an aqueous solvent, thereby forming a reaction mixture comprising a chitosan conjugate wherein the chitosan conjugate comprises a repeating unit of formula I, or a conjugate salt thereof, wherein R1 is-(C = O) (CH2) mCO2H; and m is an integer selected from 1 to 12.

This invention relates to novel immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular glycoantigens (glycoconjugates) and their uses. The immunogenic compositions of this invention will generally comprise at least one glycoconjugate derived from a Streptococcus pneumoniae serotype not found in Prevnar, Synflorix, and / or Prevnar 13. This invention also relates to the use of said novel immunogenic compositions for the vaccination of human subjects, particularly infants and the elderly, against pneumococcal infection.

The present invention relates to analytical methods for identifying and quantifying complex glycoconjugate compositions, and in particular to the analysis of polysaccharide components of glycoproteins in a sample. The present invention further relates to the use of liquid chromatography-mass spectrometry systems ("LC-MS systems") in such analytical methods, for example, for process control during glycoconjugate production.

The application provides a hybridoma cell strain secreting a monoclonal antibody against a alginate mannuronic acid tetrasaccharide epitope, a monoclonal antibody and application. In order to enhance the immunogenicity of the mannuronic acid tetrasaccharide, a glycoconjugate KLH-1 is used as an immunogen to inject and immunize a mouse, so that the mouse is stimulated to produce a specific immune response against the mannuronic acid tetrasaccharide epitope, then spleen cells of the immunized mouse are fused with myeloma cells, and after screening, an initial hybridoma cell strain is obtained; then after subcloning and specific screening, a hybridoma cell strain capable of stably secreting a monoclonal antibody of the target mannuronic acid tetrasaccharide epitope in alginate is obtained, and a monoclonal ascites antibody is further obtained. The monoclonal ascites antibody shows specific recognition and combination ability for pseudomonas aeruginosa, and the combination activity is related to the expression level of alginate on the surface of the bacteria. Therefore, the monoclonal ascites antibody can be used as a precise detection and diagnosis tool for pseudomonas aeruginosa, and can also be applied to the antibacterial treatment of pseudomonas aeruginosa infection.

The present disclosure includes methods of treating 05-associated disease or disorder, such as myasthenia gravis, with a combination that includes an antibody or antigen-binding fragment thereof that binds specifically to C5 and a C5 iRNA which is a glycoconjugate that includes a ligand having terminal N-Acetylgalactosamine (GalNAc) residues and / or N-acetylglucosamine (GIcNAc) residues; or with the C5 iRNA monotherapy.

FIELD: biotechnology.SUBSTANCE: composition for protecting or treating a human susceptible to pneumococcal infection is described, comprising: (i) at least 21 different glycoconjugates; (ii) a succinate buffer having a pH in the range of 5.0 to 7.5; (iii) sodium chloride; (iv) sodium phosphate; (iv) a surfactant; and (v) an adjuvant.EFFECT: vaccine formulation that facilitates resuspension of the vaccine for administration.71 cl, 7 dwg, 3 tbl, 6 ex

This invention discloses the preparation and application of a base-sensitive linker arm for solid-phase synthesis of polysaccharides, belonging to the fields of glycochemistry and solid-phase synthesis technology. This invention provides a base-sensitive linker arm system comprising an ester core, a linker, and a solid-phase support; one end of the ester core is connected to the solid-phase support, and the other end is connected to the linker; one end of the linker is connected to the ester core, and the other end contains exposed hydroxyl groups; the linker arm system of this invention uses phthalates or alkyl esters as the base-sensitive core structure, which can be cleaved under sodium methoxide conditions, and after hydrogenation deprotection, retains free anomeric sites at the ends of the polysaccharides, or provides amino and carboxyl groups for subsequent preparation of glycoconjugates and glycochips. During the cleavage of the linker arm, the ester protecting groups of the polysaccharide can be removed simultaneously, simplifying the deprotection step and improving efficiency and yield.

This invention belongs to the field of novel glycoconjugates and provides a method for preparing a sialic acid-gold nanomaterial composite. The method includes the following steps: S1: synthesizing a sialic acid ligand functional molecule; S2: synthesizing a PC molecule; S3: replacing the stabilizing molecule on the surface of the gold nanomaterial with a modified molecule under the action of a promoter to obtain a surface-modified material intermediate; S4: activating the surface carboxyl groups of the surface-modified material intermediate, reacting it with the PC molecule and the sialic acid ligand functional molecule, and connecting them through amide bonds. This invention provides a method for creating a sialic acid-gold nanocomposite material with a novel surface structure. The sialic acid molecule is obtained by modifying the structure of natural sialic acid molecules and can specifically recognize and bind to the SARS-CoV-2 S protein. The superhydrophilic properties of the PC group are utilized to reduce non-specific interference of complex environments on the material, while maintaining the biological effects of the sialic acid-gold nanocomposite material.

The present disclosure provides methods and compositions for using a novel class of glycan conjugates for modulating cell surface proteins and receptor complexes that can be used to engage signaling pathways within desired cell types. Such defined cell-targeting bioactive glycoligands are directed to cell engagement and activation in therapeutic applications.

A method for enhancing the immunogenicity of a protein / peptide antigen is provided, wherein the protein / peptide antigen forms a fusion protein with an Fc fragment, preferably with receptor-binding / complement-binding enhanced Fc fragment, and further forms a fusion protein glycoconjugate with a glycosyl group. In the preferred embodiment, the Fc fragment, due to alterations in its amino acid sequence and / or glycosylation, has an enhanced binding capacity to Fc receptors and / or complement protein C1q compared to its native form. Such vaccines can maintain long-term humoral and cellular immune responses, exhibiting higher cellular immune responses and producing higher titers of neutralizing antibodies in immunized animals. Using the SARS-CoV-2 RBD region as the antigen in an immunizing composition, it is formed into a fusion protein with an Fc region that has undergone amino acid sequence and fucose alteration, and further forms a fusion protein glycoconjugate with pneumococcal polysaccharide, for the prevention of SARS-CoV-2 infection-related diseases.

The present disclosure includes methods of treating C5-associated disease or disorder, such as myasthenia gravis, with a combination that includes an antibody or antigen-binding fragment thereof that binds specifically to C5 and a C5 iRNA which is a glycoconjugate that includes a ligand having terminal N-Acetylgalactosamine (GalNAc) residues and / or N-acetylglucosamine (GlcNAc) residues; or with the C5 iRNA monotherapy.

Compounds, compositions, and methods are provided for covalently linking an antibody or an antibody fragment to a cargo molecule, such as a therapeutic or a diagnostic agent, using a combination of enzymatic glycan remodeling and click chemistry. The method allows a cargo molecule to be selectively and efficiently attached post-translationally to an antibody or an antibody fragment. Also provided are antibody drug conjugates, methods of making, and uses thereof.

The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and / or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.

The present disclosure discloses a specific saccharide fragment for development of Vibrio cholerae vaccines, and belongs to the field of medicine. In the present disclosure, a saccharide fragment related to a trisaccharide of V. cholerae O100 serotype O-antigen is chemically synthesized. Combined with a glycan microarray technology, the structure-activity relationship between different saccharide fragments and antigenicity thereof is evaluated at a molecular level. Glycan microarray screening indicates that 3-hydroxybutyryl is an essential structural feature of the O-antigen. A non-reducing end disaccharide carrying 3-hydroxybutyryl is a potential minimal antigenic epitope, and the disaccharide has strong binding capacity to antibodies and a simple structure, and may serves as a specific saccharide fragment for vaccine development. A glycoconjugate vaccine designed based on the specific saccharide fragment may solve the challenges of difficulty in culturing pathogenic bacteria and heterogeneity of saccharide antigens in naturally extracted polysaccharide vaccines. The present disclosure has bright application prospects in the development of glycoconjugate V. cholerae vaccine, infection detection, and new drug development.

The present invention relates to intranasal bacterial polysaccharide conjugate nanoemulsion vaccines and methods of using the same for inducing an immune response to a bacterial polysaccharide.

The invention discloses a membrane source specific extracellular vesicle marking method and application thereof. The membrane source specific extracellular vesicle labeling method comprises the following steps: mixing and incubating a cell to be labeled and a metabolic sugar precursor containing an azide group, so that the azide group is integrated onto a sugar complex of the cell through a glycosylation pathway, incubating the cell with a first click probe, and continuing to culture to obtain the membrane source specific extracellular vesicle. And collecting and extracting the extracellular vesicles, carrying out second click chemical labeling on the surfaces of the extracellular vesicles, and carrying out signal detection and grouping analysis after labeling. According to the method disclosed by the invention, time sequence marking of'closing / marking a cell outer side site at first and then marking a new vesicle exposed site 'can be realized in the same system, endocytosis mismarking and background interference are reduced, and the method can be used for vesicle subgroup change monitoring, disease diagnosis, curative effect evaluation and drug screening related to drug treatment / drug resistance.

The invention discloses a preparation method of an icaritin diglucose conjugate, which comprises the following steps: reacting icaritin and bromoglucose in a solvent under the catalysis of an inorganic base and a phase transfer catalyst to obtain an icaritin diglucose conjugate 3; the method has the advantages of cheap and easily available initial raw materials, mild synthesis conditions, simple operation, high yield and easy industrial preparation.

The application discloses a preparation method and application of a cocktail vaccine of Acinetobacter baumannii, and belongs to the technical field of vaccine preparation. The vaccine comprises sugar conjugates formed by coupling three branched pentasaccharides of K14, K47 and K128 with diphtheria toxoid. The preparation method comprises the steps of hapten synthesis, purification, coupling with carrier protein and mixing. Experiments show that the vaccine can induce high levels of specific antibodies, significantly reduce the tissue bacterial load of mice infected with Acinetobacter baumannii, and has a wide protective effect. The application is suitable for preventing and treating various infectious diseases caused by Acinetobacter baumannii.

The present invention provides a glycoconjugate for administration to a subject in a method comprising the steps of: (i) administering a first dose of glycoconjugate; (ii) subsequently administering a second dose of glycoconjugate; wherein the amount of glycoconjugate in the first dose or first and second doses are atypically low, and also related aspects.

The present invention relates to glycyrrhizin-glycol chitosan conjugate-coated nanoparticles, islet cells, prepared using same, for transplantation, and an MRI imaging composition comprising same. If transplanted, the islet cells comprising the nanoparticles can suppress a post-transplantation immune response. The present invention can provide islet cells for transplantation that can be transplanted to a certain region by magnetic force induction and can be tracked by MRI.

The present invention relates to homing peptide-directed decorin conjugates for the treatment of epidermolysis bullosa, and corresponding methods of treatment. The use of novel homing peptides enables the targeting of the conjugates in vivo to specifically home to the skin and skin wounds by systemic administration.

This article describes oligosaccharide transferases for N-glycosylation of target proteins in vitro and in host cells. It also provides methods for using such oligosaccharide transferases, nucleic acids encoding such oligosaccharide transferases, and host cells containing such oligosaccharide transferases. Furthermore, it provides glycoconjugates produced using such oligosaccharide transferases.

The invention belongs to the field of chemical synthesis, and relates to glycosyl thioether with oxime functional groups and a preparation method and application thereof. According to the invention, glycosyl thioether with oxime functional groups is prepared, the glycosyl thioether is used as a glycosyl free radical donor, a styrene compound is used as a glycosyl acceptor substrate, and a method for synthesizing alkyl C-glycoside through visible light catalysis is established and is used for synthesizing a series of C-glycoside compounds. The oxime-bonded glycosyl thioether prepared by the invention is stable in property, the preparation method has the advantages of simplicity, convenience, high yield, wide applicable saccharide range and the like, and the oxime-bonded glycosyl thioether is applied to synthesis of carbon glycoside and has the advantages of simplicity, wide substrate application range, including various drugs and polypeptides and the like. Therefore, the glycosyl thioether provides a new thought for development of complex glycoconjugates and drugs, and further promotes industrial development of carbon glycoside medicines.

The invention provides a novel streptococcus group A oligosaccharide antigen and glycobinding protein vaccine, which is characterized in that oligosaccharide antigen containing 30-70% of N-acetyl glucamine multi-rhamnose core skeleton structure is accurately prepared through chemical synthesis, and is efficiently coupled with KLH (the loading capacity is about 215 oligosaccharide / KLH molecules); safe, efficient and broad-spectrum immune protection is realized; safety: the GlcNAc side chain modification design avoids autoimmune risks (such as acute rheumatic fever heat); high efficiency: the animal experiment antibody titer reaches 1: 12, 800; the broad spectrum is as follows: the highly conservative universal GAS oligosaccharide antigen can universally cover various serotypes, and the key synthetic route (Scheme 2, 3, 16 and 20, the yield is 22%-96%) and the loading capacity verification (HPAEC) support the technical feasibility.

The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and / or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.